公开(公告)号：US20180021314A1

公开(公告)日：2018-01-25

申请号：US15722257

申请日：2017-10-02

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA ,  Daisuke SHII

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K31/675

CPC分类号： A61K31/436 ,  A61K9/0048 ,  A61K31/675

摘要： A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.

公开(公告)号：US20190255026A1

公开(公告)日：2019-08-22

申请号：US16405249

申请日：2019-05-07

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA ,  Daisuke SHII

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K31/675

摘要： A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

公开(公告)号：US20190106393A1

公开(公告)日：2019-04-11

申请号：US16210163

申请日：2018-12-05

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Kenji KAWASHIMA ,  Yusuke YAMAZAKI ,  Shinji TAKAOKA ,  Daisuke SHII ,  Tomoko ODA ,  Takahiro MATSUYAMA

IPC分类号： C07D241/44 ,  C07F9/6509 ,  A61P29/00 ,  A61P27/02 ,  C07D403/12 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/498

CPC分类号： C07D241/44 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/675 ,  A61P27/02 ,  A61P29/00 ,  C07D403/12 ,  C07F9/650994

摘要： The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.

公开(公告)号：US20180244633A1

公开(公告)日：2018-08-30

申请号：US15753410

申请日：2016-08-25

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Kenji KAWASHIMA ,  Yusuke YAMAZAKI ,  Shinji TAKAOKA ,  Daisuke SHII ,  Tomoko ODA ,  Takahiro MATSUYAMA

IPC分类号： C07D241/44 ,  A61P27/02 ,  A61P29/00 ,  C07D403/12 ,  C07F9/6509

CPC分类号： C07D241/44 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/675 ,  A61P27/02 ,  A61P29/00 ,  C07D403/12 ,  C07F9/650994

摘要： The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.

公开(公告)号：US20160022648A1

公开(公告)日：2016-01-28

申请号：US14775019

申请日：2014-03-12

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA ,  Daisuke SHII

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K31/675

CPC分类号： A61K31/436 ,  A61K9/0048 ,  A61K31/675

摘要： A compound represented by the formula (1): wherein R1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R2 and R3 represent a methoxy group, etc., or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.

摘要翻译： 由式（1）表示的化合物：其中R1表示羟基，二甲基膦酰基氧基等; R2和R3表示甲氧基等，或其药学上可接受的盐可以降低睑板腺口周围的毛细血管扩张的分数和孔处的多个阻塞，因此其可用作预防和/或治疗 睑板腺功能障碍的代理。